US Thyroid Cancer Market: Trends and Opportunities (2015 – 2019)
Scope of the Report
The report titled “US Thyroid Cancer Market: Trends and Opportunities (2015-2019)” provides an insight into the overall thyroid cancer market of the United States of America. The report analyzes in detail the segments of Thyroid Cancer Market that includes Thyroid Cancer Diagnostics Surgeries, Thyroid Histopathology Market, Thyroid Cancer Secondary Surgery and Thyroid Cancer Hormone Replacement Market. The report assesses thyroid cancer types, stages and incidence rate of the disease and also discusses the factors that will result in the demand and growth of the market. Further, companies like Veracyte Inc., Mylan Inc., Forest Laboratories, Abott Laboratories and Oxigene Inc. are profiled in the report.
Product Coverage
Thyroid cancer, a type of malignant cancer, initiate from follicular and par follicular thyroid cells. The most effective treatment of thyroid cancer is surgical removal of thyroid gland followed by radioactive ablation and thyroid stimulating hormone (TSH) suppression therapy. Chemotherapy is also used in cases of metastasis and progressive stage of thyroid cancer. Thyroid cancer market is accelerating in the United States since 2010 and it is a disease which is fast on the rise. Incidence has more than doubled since the early 1970s, and for women, it is the cancer with the fastest-growing number of new cases.
On the back of high incidence of thyroid cancer, it is anticipated that the thyroid cancer market in US will observe impressive double digit growth in next five years. The thyroid cancer diagnosis market is segmented into diagnostic surgeries, histopathology, secondary surgery and annual new patient hormone replacement therapy. The diagnostic technology has improved since 2011 and with use of Afirma GEC test and Afirma FNA; the detection of even minor nodules has become possible.
The report titled “US Thyroid Cancer Market: Trends and Opportunities (2015-2019)” provides an insight into overall thyroid cancer sector of United States of America. The report includes detailed information on market size, installed base and geographical segmentation of overall sector. The market segmentation on basis of thyroid cancer type, stage and incidence rate is also given in detail. It also discusses key growth drivers, challenges and trends of the market. Further, companies like Veracyte Inc., Mylan Inc., Forest Laboratories, Abott Laboratories and Oxigene Inc. are profiled in the report.
The report titled “US Thyroid Cancer Market: Trends and Opportunities (2015-2019)” provides an insight into the overall thyroid cancer market of the United States of America. The report analyzes in detail the segments of Thyroid Cancer Market that includes Thyroid Cancer Diagnostics Surgeries, Thyroid Histopathology Market, Thyroid Cancer Secondary Surgery and Thyroid Cancer Hormone Replacement Market. The report assesses thyroid cancer types, stages and incidence rate of the disease and also discusses the factors that will result in the demand and growth of the market. Further, companies like Veracyte Inc., Mylan Inc., Forest Laboratories, Abott Laboratories and Oxigene Inc. are profiled in the report.
Product Coverage
- Thyroid Cancer Diagnostic Surgeries
- Thyroid Cancer Histopathology Market
- Thyroid Cancer Secondary Surgery
- Thyroid Cancer Hormone Replacement
- FNA biopsies
- Veracyte Inc.
- Mylan Inc.
- Forest Laboratories
- Abott Laboratories
- Oxigene Inc.
Thyroid cancer, a type of malignant cancer, initiate from follicular and par follicular thyroid cells. The most effective treatment of thyroid cancer is surgical removal of thyroid gland followed by radioactive ablation and thyroid stimulating hormone (TSH) suppression therapy. Chemotherapy is also used in cases of metastasis and progressive stage of thyroid cancer. Thyroid cancer market is accelerating in the United States since 2010 and it is a disease which is fast on the rise. Incidence has more than doubled since the early 1970s, and for women, it is the cancer with the fastest-growing number of new cases.
On the back of high incidence of thyroid cancer, it is anticipated that the thyroid cancer market in US will observe impressive double digit growth in next five years. The thyroid cancer diagnosis market is segmented into diagnostic surgeries, histopathology, secondary surgery and annual new patient hormone replacement therapy. The diagnostic technology has improved since 2011 and with use of Afirma GEC test and Afirma FNA; the detection of even minor nodules has become possible.
The report titled “US Thyroid Cancer Market: Trends and Opportunities (2015-2019)” provides an insight into overall thyroid cancer sector of United States of America. The report includes detailed information on market size, installed base and geographical segmentation of overall sector. The market segmentation on basis of thyroid cancer type, stage and incidence rate is also given in detail. It also discusses key growth drivers, challenges and trends of the market. Further, companies like Veracyte Inc., Mylan Inc., Forest Laboratories, Abott Laboratories and Oxigene Inc. are profiled in the report.
1. EXECUTIVE SUMMARY
2. UNITED STATES THYROID CANCER MARKET: AN INTRODUCTION
2.1 Cancer Cells
2.2 Types of Thyroid Cancer
2.3 Diagnosis
2.4 Staging
2.5 Treatment
2.5.1 Surgery
2.5.2 Radioactive Iodine Therapy
2.5.3 External Radiation Therapy
2.6 Thyroid Cancer Drugs
3. US THYROID CANCER MARKET: SIZING AND GROWTH
3.1 U.S Thyroid Cancer Market: 2010-2014
3.2 U.S Thyroid Cancer Market: 2015-2019
4. US THYROID CANCER MARKET SEGMENTATION
4.1 U.S Thyroid Cancer Diagnostic Surgeries Market
4.1.1 U.S Thyroid Cancer Diagnostic Surgeries Market: 2010-2014
4.1.2 U.S Thyroid Cancer Diagnostic Surgeries Market: 2015-2019
4.2 Thyroid Cancer Histopathology Market
4.2.1 Thyroid Cancer Histopathology Market: 2010-2014
4.2.2 Thyroid Cancer Histopathology Market: 2015-2019
4.3 Thyroid Cancer Secondary Surgery Market
4.3.1 U.S Thyroid Cancer Secondary Surgery Market: 2010-2014
4.3.2 U.S Thyroid Cancer Secondary Surgery Market: 2015-2019
4.4 Thyroid Cancer Hormone Replacement Market
4.4.1 U.S Thyroid Cancer Hormone Replacement Market: 2010-2014
4.4.2 U.S Thyroid Cancer Hormone Replacement Market: 2015-2019
4.5 U.S thyroid cancer market: By Cancer Type
4.6 U.S thyroid cancer market: Cases by Cancer Stage
5. U.S THYROID CANCER DIAGNOSIS MARKET: BY FNA VOLUME
5.1 U.S Thyroid Cancer Diagnosis Market- FNA Volume: 2010-2014
5.2 U.S Thyroid Cancer Diagnosis Market- FNA Volume: 2015-2019
6. MARKET DYNAMICS: US THYROID CANCER DIAGNOSIS MARKET
6.1 Growth Drivers
6.1.1 Fast growing cancer market in the US
6.1.2 Growing Middle Age population
6.1.3 Escalating Healthcare Expenditure in the US
6.1.4 Economic Growth
6.2 Challenges
6.2.1 Risk of surgery
6.2.2 Regulatory issues
6.3 Trends
6.3.1 Rate of survival after diagnosis
4.3.2 Provides cost savings to healthcare suppliers and patients
6.3.3 Early approval of Lenvima presents additional growth opportunities
6.3.4 Launch of Affirma test and GEC
6.3.5 Thyroid Nodules More Common in Women
7. COMPETITIVE LANDSCAPE: U.S THYROID CANCER DIAGNOSIS MARKET
8. COMPANY PROFILES: U.S THYROID CANCER DIAGNOSIS MARKET
8.1 Veracyte Inc.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business strategies
8.2 Oxigene Inc.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business strategies
8.3 Forest Laboratories
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business strategies
8.4 Mylan Inc.
8.4.1 Business Overview
8.4.2 Financial overview
8.4.3 Business strategies
8.5 Abbott Laboratories
8.5.1 Business Overview
8.5.2 Financial Overview
8.5.3 Business Strategy
2. UNITED STATES THYROID CANCER MARKET: AN INTRODUCTION
2.1 Cancer Cells
2.2 Types of Thyroid Cancer
2.3 Diagnosis
2.4 Staging
2.5 Treatment
2.5.1 Surgery
2.5.2 Radioactive Iodine Therapy
2.5.3 External Radiation Therapy
2.6 Thyroid Cancer Drugs
3. US THYROID CANCER MARKET: SIZING AND GROWTH
3.1 U.S Thyroid Cancer Market: 2010-2014
3.2 U.S Thyroid Cancer Market: 2015-2019
4. US THYROID CANCER MARKET SEGMENTATION
4.1 U.S Thyroid Cancer Diagnostic Surgeries Market
4.1.1 U.S Thyroid Cancer Diagnostic Surgeries Market: 2010-2014
4.1.2 U.S Thyroid Cancer Diagnostic Surgeries Market: 2015-2019
4.2 Thyroid Cancer Histopathology Market
4.2.1 Thyroid Cancer Histopathology Market: 2010-2014
4.2.2 Thyroid Cancer Histopathology Market: 2015-2019
4.3 Thyroid Cancer Secondary Surgery Market
4.3.1 U.S Thyroid Cancer Secondary Surgery Market: 2010-2014
4.3.2 U.S Thyroid Cancer Secondary Surgery Market: 2015-2019
4.4 Thyroid Cancer Hormone Replacement Market
4.4.1 U.S Thyroid Cancer Hormone Replacement Market: 2010-2014
4.4.2 U.S Thyroid Cancer Hormone Replacement Market: 2015-2019
4.5 U.S thyroid cancer market: By Cancer Type
4.6 U.S thyroid cancer market: Cases by Cancer Stage
5. U.S THYROID CANCER DIAGNOSIS MARKET: BY FNA VOLUME
5.1 U.S Thyroid Cancer Diagnosis Market- FNA Volume: 2010-2014
5.2 U.S Thyroid Cancer Diagnosis Market- FNA Volume: 2015-2019
6. MARKET DYNAMICS: US THYROID CANCER DIAGNOSIS MARKET
6.1 Growth Drivers
6.1.1 Fast growing cancer market in the US
6.1.2 Growing Middle Age population
6.1.3 Escalating Healthcare Expenditure in the US
6.1.4 Economic Growth
6.2 Challenges
6.2.1 Risk of surgery
6.2.2 Regulatory issues
6.3 Trends
6.3.1 Rate of survival after diagnosis
4.3.2 Provides cost savings to healthcare suppliers and patients
6.3.3 Early approval of Lenvima presents additional growth opportunities
6.3.4 Launch of Affirma test and GEC
6.3.5 Thyroid Nodules More Common in Women
7. COMPETITIVE LANDSCAPE: U.S THYROID CANCER DIAGNOSIS MARKET
8. COMPANY PROFILES: U.S THYROID CANCER DIAGNOSIS MARKET
8.1 Veracyte Inc.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business strategies
8.2 Oxigene Inc.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business strategies
8.3 Forest Laboratories
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business strategies
8.4 Mylan Inc.
8.4.1 Business Overview
8.4.2 Financial overview
8.4.3 Business strategies
8.5 Abbott Laboratories
8.5.1 Business Overview
8.5.2 Financial Overview
8.5.3 Business Strategy
LIST OF FIGURES
Figure 1: U.S Thyroid Cancer Market: 2010-2014
Figure 2: U.S Thyroid Cancer Market Segmentation: 2014
Figure 3: U.S Thyroid Cancer Market: 2015-2019
Figure 4: U.S Thyroid Cancer Diagnostic surgeries: 2010-2014- US$ Million
Figure 5: U.S Thyroid Cancer Diagnostic surgeries: 2015-2019- US$ Billion
Figure 6: U.S Thyroid Cancer Histopathology Market: 2010-2014-US$ Million
Figure 7: U.S Thyroid Cancer Histopathology Market: 2015-2019-US$ Million
Figure 8: U.S Thyroid Cancer Secondary Surgery Market: 2010-2014-US$ Million
Figure 9: U.S Thyroid Cancer Secondary Surgery Market: 2015-2019-US$ Million
Figure 10: U.S Thyroid Cancer Hormone Replacement Market: 2010-2014-US$ Million
Figure 11: U.S Thyroid Cancer Hormone Replacement Market: 2015-2019-US$ Million
Figure 12: Incidence of Thyroid Cancer Types: 2013
Figure 13: Percent of Cases by Stage of Cancer (US Patients, 2010-2013)
Figure 14: U.S Thyroid Cancer Diagnosis Market- FNA Volume: 2010-2014
Figure 15: Cancer Type Result From FNA in Percentage
Figure 136 U.S Thyroid Cancer Diagnosis Market- FNA Volume: 2015-2019
Figure 17: Increasing Thyroid Cancer Incidence: 2009-2013
Figure 18: Increasing Incidence in Middle Age Population
Figure 19: U.S Middle Age population-2010-2014
Figure 20: The US Healthcare Expenditure Per Capita (2006-2013)
Figure 21: U.S GDP Per capita- U.S$: 2010-2013
Figure 22: 5- Year Relative Survival Rate According To Thyroid Cancer Stage
Figure 23: new cases and fatalities in women and men with thyroid cancer: 2013
Figure 24: Veracyte’s Revenue-U.S$ Million: 2011-2014
Figure 25: Veracyte’s Net Income (loss) - US$ Million: 2011-2014
Figure 26: Veracyte’s R$D Expenditure-US$ Million: 2011-2013
Figure 27: Oxigene Revenue-U.S$ Million: 2012-2013
Figure 28: Oxigene’s Net Income (loss) -U.S$ Million: 2011-2013
Figure 29: Forest Lab’s Revenue-U.S$ Billion: 2011-2013
Figure 30: Oxigene’s Net Income (loss) - US$ Million: 2011-2013
Figure 31: Mylan Inc. Revenue-US$ Billion: 2011-2013
Figure 32: Oxigene’s Net Income -US$ Billion: 2011-2013
Figure 33: Abbott Laboratories Revenue share by Business Unit (2013)
Figure 34: Abbott Laboratories Revenue and Net Income (2009-2013)-US$ Billion
Figure 1: U.S Thyroid Cancer Market: 2010-2014
Figure 2: U.S Thyroid Cancer Market Segmentation: 2014
Figure 3: U.S Thyroid Cancer Market: 2015-2019
Figure 4: U.S Thyroid Cancer Diagnostic surgeries: 2010-2014- US$ Million
Figure 5: U.S Thyroid Cancer Diagnostic surgeries: 2015-2019- US$ Billion
Figure 6: U.S Thyroid Cancer Histopathology Market: 2010-2014-US$ Million
Figure 7: U.S Thyroid Cancer Histopathology Market: 2015-2019-US$ Million
Figure 8: U.S Thyroid Cancer Secondary Surgery Market: 2010-2014-US$ Million
Figure 9: U.S Thyroid Cancer Secondary Surgery Market: 2015-2019-US$ Million
Figure 10: U.S Thyroid Cancer Hormone Replacement Market: 2010-2014-US$ Million
Figure 11: U.S Thyroid Cancer Hormone Replacement Market: 2015-2019-US$ Million
Figure 12: Incidence of Thyroid Cancer Types: 2013
Figure 13: Percent of Cases by Stage of Cancer (US Patients, 2010-2013)
Figure 14: U.S Thyroid Cancer Diagnosis Market- FNA Volume: 2010-2014
Figure 15: Cancer Type Result From FNA in Percentage
Figure 136 U.S Thyroid Cancer Diagnosis Market- FNA Volume: 2015-2019
Figure 17: Increasing Thyroid Cancer Incidence: 2009-2013
Figure 18: Increasing Incidence in Middle Age Population
Figure 19: U.S Middle Age population-2010-2014
Figure 20: The US Healthcare Expenditure Per Capita (2006-2013)
Figure 21: U.S GDP Per capita- U.S$: 2010-2013
Figure 22: 5- Year Relative Survival Rate According To Thyroid Cancer Stage
Figure 23: new cases and fatalities in women and men with thyroid cancer: 2013
Figure 24: Veracyte’s Revenue-U.S$ Million: 2011-2014
Figure 25: Veracyte’s Net Income (loss) - US$ Million: 2011-2014
Figure 26: Veracyte’s R$D Expenditure-US$ Million: 2011-2013
Figure 27: Oxigene Revenue-U.S$ Million: 2012-2013
Figure 28: Oxigene’s Net Income (loss) -U.S$ Million: 2011-2013
Figure 29: Forest Lab’s Revenue-U.S$ Billion: 2011-2013
Figure 30: Oxigene’s Net Income (loss) - US$ Million: 2011-2013
Figure 31: Mylan Inc. Revenue-US$ Billion: 2011-2013
Figure 32: Oxigene’s Net Income -US$ Billion: 2011-2013
Figure 33: Abbott Laboratories Revenue share by Business Unit (2013)
Figure 34: Abbott Laboratories Revenue and Net Income (2009-2013)-US$ Billion
LIST OF TABLES
Table 1: TNM Classification for Differentiated Thyroid Cancer
Table 2: FDA Approved drugs for thyroid cancer treatment
Table 3: Investigational agents for thyroid cancer
Table 4: 5-Year and 10-Year Surviaval Rate by cancer type
Table 5: U.S Major Players of Thyroid Cancer Market
Table 1: TNM Classification for Differentiated Thyroid Cancer
Table 2: FDA Approved drugs for thyroid cancer treatment
Table 3: Investigational agents for thyroid cancer
Table 4: 5-Year and 10-Year Surviaval Rate by cancer type
Table 5: U.S Major Players of Thyroid Cancer Market
